Novartis' Kisqali succeeds in early breast cancer trial

27 March 2023

Novartis (NOVN: VX) saw its shares rise nearly 6% in early trading, as the Swiss pharma giant announced that its cancer medicine Kisqali (ribociclib) has met its primary endpoint in a pivotal trial in patients with early breast cancer (EBC).

The successful interim results from the NATALEE Phase III trial are the first for Kisqali in EBC, which represents more than 90% of patients with breast cancer.

The trial’s primary endpoint was invasive disease-free survival (iDFS) – indicating a patient’s cancer has not returned – in patients with stage II and III HR+/HER2- EBC, regardless of nodal involvement. This represents the broadest patient population of any CDK4/6 inhibitor trial to date.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK